Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-337-6 | CAS number: 119-61-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1998 - 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: A NTP (National Toxicology Program) study. Test method equivalent to OECD 414. GLP study.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 002
- Report date:
- 2002
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Benzophenone
- EC Number:
- 204-337-6
- EC Name:
- Benzophenone
- Cas Number:
- 119-61-9
- Molecular formula:
- C13H10O
- IUPAC Name:
- benzophenone
- Details on test material:
- - Name of test material (as cited in study report): Benzophenone
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: methylcellulose
- Details on exposure:
- VEHICLE
- Concentration in vehicle: 0.5%
- Amount of vehicle (if gavage): 5 mL/kg - Duration of treatment / exposure:
- Gestational days (GD) 6 through 19
- Frequency of treatment:
- Once daily
- Duration of test:
- On gd 20, timed-mated females were sacrificed.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
100, 200, or 300 mg/kg/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 25 to 26 time-mated female rats per group.
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose selection was based on a screening study in which Sprague-Dawley-derived rats were treated by gavage with benzophenone (0, 25, 50, 100, 200, or 300 mg/kg body weight/day) on GD 6 through 19. Maternal toxicity was found at all doses, but evidence of developmental toxicity was limited to a 6-8% decrease for average fetal body weight per litter (not statistically significant) at the high dose.
Examinations
- Maternal examinations:
- Dams were monitored at regular intervals throughout gestation for clinical signs, feed and water intake, and body weight.
At necropsy on GD 20, the following were recorded: maternal clinical condition; body, liver, paired kidney weights. - Ovaries and uterine content:
- At necropsy on GD 20, the following were recorded: gravid uterine weights; pregnancy status; and number of corpora lutea. In the gravid uterus, the numbers of resorbed, dead, or live fetuses were recorded.
- Fetal examinations:
- All live fetuses were weighed, sexed, and examined for external morphological anomalies. Approximately one-half of the fetuses were examined for visceral anomalies, including internal head structures, and the remaining fetuses were examined for skeletal anomalies.
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes. Remark: (reduced body weights, food and water consumption; and increased liver and kidney weight)
Details on maternal toxic effects:
MORTALITY
No treatment-related maternal deaths occurred in this study.
CLINICAL SIGNS
Clinical signs at all doses of benzophenone included lethargy, pilo-erection, weight loss and rooting in the bedding after dosing.
BODY WEIGHT AND BODY WEIGHT GAIN
Maternal body weight was decreased at the low dose on GD 9, 12, and 15, at the mid dose on GD 9 and 12, and at the high dose on GD 9, 12, 15, 18, 19, and 20 at sacrifice. Decreased maternal weight gain was observed at all doses from gd 6 to 9, and at the high dose from gd 9 to 12. In-creased weight gain was noted at the mid dose (GD 9 to 12 and 19 to 20) and at the high dose (GD 18 to 19 and 19 to 20). Maternal body weight gain during treatment and gestation was decreased only at the high dose, while gestational weight gain corrected for gravid uterine weight was reduced at all doses.
FEED AND WATER INTAKE
Maternal relative feed intake (g/kg/day) was decreased at all doses from gd 6 to 9, and at the mid and high doses from gd 9 to 12. Rebound increases in feed intake were noted at all doses of benzophenone from gd 15 to 18, and 18 to 19. The high dose showed a significant decrease in relative feed intake for the treatment period as a whole. Maternal relative water intake (g/kg/day) was increased at the low dose (gd 15 to 18 and 18 to 19), and the mid and high doses (gd 12 to 15, 15 to 18, 18 to 19, and 19 to 20). Relative water intake for the treatment period as a whole (gd 6 to 20) was not affected.
ORGAN WEIGHTS
Gravid uterine weight was not affected. Maternal liver and kidney weights (absolute and/or relative) were significantly increased at all doses.
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- LOAEL
- Effect level:
- 100 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- NOAEL
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes. Remark: (decreased fetal body weight)
Details on embryotoxic / teratogenic effects:
BODY WEIGHT
Average fetal body weight per litter exhibited decreasing dose-response trends (males, females, and both sexes combined). At the high dose, a 6.5% decrease for male fetal body weight was statistically significant; a 5% decrease for female fetal body weight was biologi-cally significant, but did not reach statistical significance.
DEVELOPMENTAL PARAMETERS
Benzophenone had no adverse effect on prenatal viability or the overall incidences of fetal malformations or variations. The incidence of unossified sternebrae was increased at all doses of benzophenone, and the incidence of extra rib (full or rudimentary, combined) on Lumbar I was increased at the mid and high doses. However, neither of these skeletal variations exhibited a significant dose-response relationship.
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In a pre-natal developmental study in rats, the maternal toxicity LOAEL was determined to be 100 mg/kg/day based on reduced body weights, food and water consumption; and increased liver and kidney weight at all dose levels. No clearly defined LOAL and NOAEL were achieved for developmental toxicity (lower fetal body weight in 300 mg/kg bw/day, incidence of unossified sternebrae at all doses). Nevertheless, the effects were limited to mild developmental delays with a high probability of recovery during early postnatal development.
- Executive summary:
The developmental toxic potential of the test substance to Sprague-Dawley rats was assessed by the National Toxicology Program with a test method similar to OECD 414. Benzophenone (100, 200, or 300 mg/kg bw/day) or its vehicle (0.5% methylcellulose) was administered to female CD rats by gavage on gd 6 through 19. The dose volume was 5 mL/kg. 25 to 26 timed-mated rats were assigned to each group. Dams were monitored at regular intervals throughout gestation for clinical signs, feed and water intake, and body weight. At necropsy on GD 20, the following were recorded: maternal clinical condition; body, liver, paired kidney and gravid uterine weights; pregnancy status; and number of corpora lutea. In the gravid uterus, the numbers of resorbed, dead, or live fetuses were recorded. All live fetuses were weighed, sexed, and examined for external morphological anomalies. Approximately one-half of the fetuses were examined for visceral anomalies, including internal head structures, and the remaining fetuses were examined for skeletal anomalies. Maternal toxicity was noted at greater than or equal to 100 mg/kg bw/day administered on GD 6 through 19. Clinical signs were observed and maternal liver and kidney weights were significantly increased in all dosed groups. Reduced maternal body weight gain and decreased feed consumption were observed in the 300 mg/kg bw/day. Thus, the maternal toxicity LOAEL was 100 mg/kg/day and the NOAEL was not determined. Test item had no adverse effects on prenatal viability or overall incidences of fetal malformations or variations. The average fetal body weight per litter in the 300 mg/kg bw/day group was significantly lower than that in the vehicle controls. The incidences of unossified sternebrae were increased at all doses of benzophenone, and the incidences of extra rib on Lumbar I were increased in the 200 and 300 mg/kg groups. Although, clearly defined NOAEL and LOAEL values for developmental toxicity were not achieved, the effects were limited to mild developmental delays with a high probability of recovery during early postnatal development.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.